K. Focht

发表

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone

M. Davies, J. Frias, G. Golm, 2017, Diabetes, obesity & metabolism.

Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP 2 D 6 Extensive and Poor Metabolizers A Randomized , Open-Label , Two-Period , Parallel-Group , Crossover Study

S. Preskorn, A. Nichols, K. Focht, 2012 .

Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP2D6 Extensive and Poor Metabolizers

S. Preskorn, A. Nichols, K. Focht, 2011, Clinical drug investigation.

Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

B. Dunlop, P. Ninan, S. Kornstein, 2013, The Journal of clinical psychiatry.

Monotherapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone

M. Davies, J. Frias, G. Golm, 2017 .

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.

S. Preskorn, R. Fayyad, A. Nichols, 2013, The Journal of clinical psychiatry.

Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial.

M. Thase, A. Clayton, E. Hwang, 2014, The Journal of clinical psychiatry.

Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder

M. Thase, P. Ninan, S. Kornstein, 2010, Menopause.

Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo

B. Dunlop, S. Lubaczewski, C. Guico-Pabia, 2011, Journal of clinical psychopharmacology.

Assessing the pharmacokinetics of venlafaxine ER 75 mg and desvenlafaxine 50 mg in CYP2D6 extensive and poor metabolizers

S. Preskorn, P. Ninan, A. Nichols, 2010 .

Spatiotemporal profile of atrophy in the first year following moderate‐severe traumatic brain injury

J. Gee, J. Duda, J. Whyte, 2023, Human brain mapping.

Open-Label Treatment with Desvenlafaxine in Postmenopausal Women with Major Depressive Disorder Not Responding to Acute Treatment with Desvenlafaxine or Escitalopram

M. Thase, S. Kornstein, C. Soares, 2011, CNS Drugs.

Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo

B. Dunlop, S. Lubaczewski, C. Guico-Pabia, 2011, Journal of clinical psychopharmacology.